Article
Critical Care Medicine
Yosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Masahiro Seike, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Koichi Hagiwara, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemondo
Summary: The combination treatment of bevacizumab and erlotinib did not prolong overall survival in patients with metastatic EGFR-mutant NSCLC, but both treatment groups showed relatively long survival durations.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Oncology
Yamin Shu, Qilin Zhang, Xucheng He, Li Chen
Summary: The study evaluated the cost-effectiveness of gefitinib plus chemotherapy versus gefitinib alone for advanced NSCLC patients with EGFR mutations in China. The base case analysis showed that gefitinib plus chemotherapy was a cost-effective treatment option with an ICER lower than the accepted WTP threshold. Sensitivity analyses confirmed the robustness of the results, demonstrating the advantages of gefitinib plus chemotherapy over gefitinib alone.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Oncology
Qiang Wu, Wuxia Luo, Wen Li, Ting Wang, Lin Huang, Feng Xu
Summary: This meta-analysis indicated that the combination of first-generation EGFR-TKI and CT significantly improves objective response rate (ORR) and prolongs progress-free survival (PFS) and overall survival (OS) in patients with advanced EGFR-mutated NSCLC, compared to EGFR-TKI monotherapy. Despite the increased incidence of chemotherapy-induced toxicities in the combination group, it is well tolerated and clinically manageable.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
D. Planchard, P. A. Janne, Y. Cheng, J. C. -H. Yang, N. Yanagitani, S-W Kim, S. Sugawara, Y. Yu, Y. Fan, S. L. Geater, K. Laktionov, C. K. Lee, N. Valdiviezo, S. Ahmed, J-M Maurel, I Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, A. Todd, K. Kobayashi
Summary: The study indicates that first-line treatment with osimertinib-chemotherapy significantly prolongs progression-free survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue
Summary: In this study, gefitinib plus chemotherapy was compared with gefitinib monotherapy in patients with non-small-cell lung cancer. The results showed that gefitinib plus chemotherapy significantly improved progression-free survival and had good long-term tolerability.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Alexis B. Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, Olivier Molinier, Elisabeth Quoix, Henri Berard, Josiane Otto, Isabelle Rault, Denis Moro-Sibilot, Judith Raimbourg, Elodie Amour, Franck Morin, Jose Hureaux, Lionel Moreau, Didier Debieuvre, Hugues Morel, Aldo Renault, Eric Pichon, Benjamin Huret, Sandrine Charpentier, Marc G. Denis, Jacques Cadranel
Summary: The addition of cetuximab to afatinib in the treatment of treatment-naive advanced EGFR-mutant NSCLC did not show any significant improvement in efficacy, suggesting that further investigation into this combination therapy may not be warranted.
CLINICAL CANCER RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Renxian Xie, Hongxin Huang, Tong Chen, Xuehan Huang, Chuangzhen Chen
Summary: This study found that the addition of pelareorep to traditional chemotherapy did not significantly improve overall survival, progression-free survival, or objective response rate in patients with advanced solid tumors. However, it did increase adverse events in all grades without a discernible difference in serious adverse events between the two treatment arms.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Andres F. Cardona, Camila Ordonez-Reyes, Alejandro Ruiz-Patino, Juan Esteban Garcia-Robledo, Lucia Zatarain Barron, Gonzalo Recondo, Leonardo Rojas, Luis Corrales, Claudio Martin, Feliciano Barron, Carolina Sotelo, July Rodriguez, Luisa Ricaurte, Christian Rolfo, Jenny Avila, Diana Mayorga, Pilar Archila, Jorge Otero, Luis Mas, Maritza Bermudez, Tatiana Gamez, Hernan Carranza, Carlos Vargas, Rafael Rosell, Oscar Arrieta
Summary: The addition of bevacizumab to EGFR-TKIs resulted in a significantly higher overall response rate and longer progression-free survival in advanced NSCLC patients with EGFR mutation and BIM deletion. Further prospective studies are needed to confirm these findings.
JCO PRECISION ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Zhan-Jie Zhang, Liang-Liang Shi, Xiao-Hua Hong, Bo-Ya Xiao, Guo-He Lin, Quentin Liu, Bi-Cheng Wang
Summary: This study aims to determine the optimal treatment strategy for locoregionally advanced nasopharyngeal carcinoma (LANPC). The results suggest that induction chemotherapy followed by concurrent chemoradiotherapy (IC+CCRT) is the preferred primary definitive therapy for patients with LANPC.
Article
Oncology
Ya Chen, Zhengyu Yang, Yanan Wang, Minjuan Hu, Bo Zhang, Yanwei Zhang, Fangfei Qian, Wei Zhang, Baohui Han
Summary: The study showed that adding chemotherapy or antiangiogenic therapy to pembrolizumab could significantly prolong progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) compared to pembrolizumab alone. EGFR (L858R) may be a positive prognostic factor for PFS, while high PD-L1 expression may be a positive prognostic factor for OS.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Shiqi Mao, Fei Zhou, Yiwei Liu, Shuo Yang, Bin Chen, Jian Xu, Fengying Wu, Xuefei Li, Chao Zhao, Wanying Wang, Qian Liu, Xiaofei Yu, Keyi Jia, Chuchu Shao, Caicun Zhou, Guanghui Gao, Shengxiang Ren
Summary: In previously treated advanced NSCLC patients, the combination of ICI and chemotherapy showed superior efficacy compared to ICI monotherapy, particularly in patients with negative PD-L1 expression. The addition of chemotherapy did not increase immune-related adverse events, indicating the potential benefits of this combination therapy. Further research is warranted to validate these findings.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Janne
Summary: This article reports the discovery and early clinical development of Sunvozertinib (DZD9008), a potential treatment option for EGFRexon20ins NSCLC.
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Summary: This study compared the relative survival rate of gefitinib, erlotinib, and afatinib in EGFR-mutated advanced lung adenocarcinoma patients in Taiwan. Afatinib showed better overall survival and time to treatment failure outcomes compared to gefitinib and erlotinib, especially in patients with initial brain metastases.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Rui Wang, Qiang Wu
Summary: The combination therapy of gefitinib plus pemetrexed/platinum has been shown to significantly improve progression-free survival and overall survival in advanced lung adenocarcinoma patients with EGFR mutation, with low occurrence of severe adverse events.
ONCOTARGETS AND THERAPY
(2022)